Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Angiogenesis at the interface between basic and clinical research.

A Albini1, D Noonan, L Santi

  • 1National Institute for Cancer Research, Advanced Biotechnologies Center, Genova, Italy.

The International Journal of Biological Markers
|February 12, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Moderate physical activity during neoadjuvant chemotherapy in breast cancer patients: effect on cancer-related inflammation and pathological complete response-the Neo-Runner study": [ESMO Open 9 (2024) 10.1016/j.esmoop.2024.103665].

ESMO open·2024
Same author

Moderate physical activity during neoadjuvant chemotherapy in breast cancer patients: effect on cancer-related inflammation and pathological complete response-the Neo-Runner study.

ESMO open·2024
Same author

Search for Resonances Decaying to Three W Bosons in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2022
Same author

Probing Charm Quark Dynamics via Multiparticle Correlations in Pb-Pb Collisions at sqrt[s_{NN}]=5.02  TeV.

Physical review letters·2022
Same author

First Search for Exclusive Diphoton Production at High Mass with Tagged Protons in Proton-Proton Collisions at sqrt[s]=13  TeV.

Physical review letters·2022
Same author

Observation of the B_{c}^{+} Meson in Pb-Pb and pp Collisions at sqrt[s_{NN}]=5.02  TeV and Measurement of its Nuclear Modification Factor.

Physical review letters·2022
Same journal

The diagnostic and predictive value of miR-145-3p in gastric cancer and its regulation of gastric cancer progression via targeting CREB1.

The International journal of biological markers·2026
Same journal

PFKP: A biomarker for prognosis, response to treatment and immune function of breast cancer.

The International journal of biological markers·2026
Same journal

Luminex assay of plasma IL-6, TNF-α, leptin, and adiponectin: Impact of anticoagulants, single-well analysis, and freeze-thaw stability.

The International journal of biological markers·2026
Same journal

Expression of concern: "RIPK4 is Downregulated in Poorly Differentiated Tongue Cancer and is Associated with Migration/Invasion and Cisplatin-Induced Apoptosis".

The International journal of biological markers·2026
Same journal

Association of NF-kappaBIA rs696 gene polymorphism with breast cancer risk in Bangladeshi women: A case-control study.

The International journal of biological markers·2026
Same journal

Circulating tumor cells and tumor-derived cell-free DNA in cancer management: Clinical evidence, limitations, and future directions.

The International journal of biological markers·2026
See all related articles

Antiangiogenesis therapy rapidly advances, targeting endothelial cells with novel inhibitors. Research explores altering chemotherapy and gene therapy for improved anti-angiogenesis treatments.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Antiangiogenesis research has rapidly progressed from laboratory discovery to clinical application.
  • Numerous angiogenesis inhibitors are currently in clinical trials, with ongoing development of new compounds.
  • Endothelial cells are the primary targets for most antiangiogenesis agents, which inhibit key functions like proliferation and migration.

Purpose of the Study:

  • To review the current landscape of antiangiogenesis therapies.
  • To discuss the targeting of endothelial cells by various therapeutic strategies.
  • To explore the potential of modified chemotherapy and gene therapy in antiangiogenesis.

Main Methods:

  • Review of current clinical trials and therapeutic strategies in antiangiogenesis.

Related Experiment Videos

  • Analysis of endothelial cell functions targeted by angiogenesis inhibitors.
  • Investigation of alternative administration schedules for chemotherapy.
  • Exploration of gene therapy approaches for delivering angiogenesis inhibitors.

    • Main Results:

    • A wide array of angiogenesis inhibitors are in clinical trials targeting endothelial cell functions.
    • Existing chemotherapeutic agents can be repurposed for antiangiogenesis by adjusting dosage and administration.
    • Gene therapy presents a promising avenue for delivering novel antiangiogenesis proteins.

    Conclusions:

    • Antiangiogenesis is a rapidly evolving field with diverse therapeutic strategies.
    • Targeting endothelial cells remains central to developing effective antiangiogenesis treatments.
    • Modified chemotherapy and gene therapy offer potential advancements in antiangiogenesis therapy.